Abstracts tagged "SLE and economics"

Abstract Number: 2811 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Damage Accrual in a Nationwide Canadian SLE Cohort
May Choi¹, Yvan St. Pierre², Murray Urowitz³, Dafna D Gladman⁴, Sasha Bernatsky⁵, Evelyne Vinet⁶, Christian Pineau⁷, John G Hanly⁸, Christine A. Peschken⁹, Paul R. Fortin¹⁰, Michelle Jung¹¹, Claire Barber¹², Susan Elliott¹³, Jenna Dixon¹⁴ and Ann E. Clarke¹¹, ¹University of Calgary, Calgary, AB, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Centre for Prongosis Studies in The Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁶Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁷Rheumatology, MUHC, Montreal, QC, Canada, ⁸Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁹RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ¹⁰Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ¹¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹²Medicine, University of Calgary, Calgary, AB, Canada, ¹³GEOGRAPHY AND ENVIRONMENTAL MANAGEMENT, University of Waterloo, Waterloo, ON, Canada, ¹⁴Geography and Environmental Management, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: We describe the costs associated with damage states in a Canadian-wide SLE cohort using multi-state modeling, which provides a dynamic representation of damage accrual…
Abstract Number: 2925 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann E. Clarke¹, Ian N. Bruce², Murray Urowitz³, John G. Hanly⁴, Yvan St.Pierre⁵, Sang-Cheol Bae⁶, Sasha Bernatsky⁷, Dafna D Gladman⁸, Jorge Sanchez-Guerrero⁹, Paul R. Fortin¹⁰, Juanita Romero-Diaz¹¹, Michelle Petri¹², Rosalind Ramsey-Goldman¹³, Cynthia Aranow¹⁴, Søren Jacobsen¹⁵, Daniel J. Wallace¹⁶, Joan T. Merrill¹⁷, S. Sam Lim¹⁸, Ola Nived¹⁹, Andreas Jönsen²⁰, Susan Manzi²¹, Thomas Stoll²², Christine A. Peschken²³, David A. Isenberg²⁴, Anisur Rahman²⁵, Li Su²⁶ and Vernon Farewell²⁷, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Centre for Prongosis Studies in The Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ¹⁰Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ¹¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ¹²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹³FSM, Northwestern University, Chicago, IL, ¹⁴Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Department of Rheumatology, University Hospital, Lund, Sweden, ²⁰Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden, ²¹Medicine, Allegheny Health Network, Pittsburgh, PA, ²²Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ²³RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²⁶Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ²⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Little is known about the association of healthcare costs and damage accrual. We describe the costs associated with damage progression using multi-state modeling. Methods:…
Abstract Number: 1769 • 2013 ACR/ARHP Annual Meeting
Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden
Andreas Jönsen¹, Anders A. Bengtsson¹, Christine Bengtsson², Iva Gunnarsson³, Johanna Gustafsson³, Frida Hjalte⁴, Dag Leonard⁵, Susanne Pettersson³, Solbritt Rantapää Dahlqvist⁶, Lars Rönnblom⁷, Christopher Sjöwall⁸, Katarina Steen Carlsson⁹, Elisabet Svenungsson¹⁰, Minna Willim¹¹ and Ola Nived¹², ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dpt of Public Health and Clinical Medicine, Umeå University, Rheumatology, Umeå, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴The Swedish Institute for Health Economics,, Health Economy, Lund, Sweden, ⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁶Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁸Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁹The Swedish Institute of Health Economics, Health Economy, Lund, Sweden, ¹⁰Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ¹¹Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, ¹²Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden
Background/Purpose: To study direct and indirect costs for patients with Systemic Lupus Erythematosus (SLE) ín five defined cohorts with nationwide spread in Sweden, and to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].